Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Targeting Inflammation In Atherosclerosis After Darapladib: Does The IL-6 Pathway Hold The Answer?

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Targeting inflammation appears to be a promising complementary approach to lipid-lowering drugs in atherosclerosis, but the question of which pathway in a complex system to target remains open. The failure of GlaxoSmithKline’s darapladib in the STABILITY trial may have dealt a fatal blow to phospholipase A2 enzymes as targets, but the interleukin-6 pathway is gaining attention with the ongoing CANTOS study of Novartis’ canakinumab and the NHLBI’s CIRT study of low-dose methotrexate.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts